NGD-4715 is a drug developed by Neurogen, which acts as a selective, non-peptide Antagonist (pharmacology), antagonist at the melanin concentrating hormone Receptor (biochemistry), receptor Melanin-concentrating hormone receptor 1, MCH₁. In animal models it has anxiolytic, antidepressant, and anorectic effects, and it has successfully passed Phase I clinical trials in humans. Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among its key assets. All four laboratories were closed and sold, and no employees were retained. The structure of NGD-4715 has been confused with for example 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine.

References

Antidepressants Anxiolytics Anorectics Pyridines Phenol ethers Abandoned drugs {{anxiolytic-stub